Siglita™

Sitagliptin
DPP-4 Inhibitor (Antidiabetic Preparations)

Indication:

Management of type 2 diabetes mellitus.

Dosage & Administration:

The recommended dose of Siglita^™ is 100 mg once daily. Siglita^™ can be taken with or without food.
For patients with mild renal insufficiency (creatinine clearance [CrCl] 50 mL/min) no dosage adjustment for Siglita^™ is required.
For patients with moderate renal insufficiency (CrCl 30 to <50 mL/min), the dose of Siglita^™ is 50 mg once daily.

For patients with severe renal insufficiency (CrCl <30 mL/min) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of Siglita^™ is 25 mg once daily.
Siglita^™ may be administered without regard to the timing of hemodialysis.

Preparation:

Siglita^™ Tablet: Box containing 20 tablets in blister pack.